Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6444 - 6444

Published: June 11, 2024

Cancer represents a significant threat to human health, and traditional chemotherapy or cytotoxic therapy is no longer the sole preferred approach for managing malignant tumors. With advanced research into immunogenicity of tumor cells growing elderly population, immunotherapy has emerged as prominent therapeutic option. Its significance in treating cancer patients increasingly recognized. In this study, we review conceptual classifications benefits immunotherapy, discuss recent developments new drugs clinical progress treatment through various immunotherapeutic modalities with different mechanisms. Additionally, explore impact immunosenescence on effectiveness propose innovative effective strategies rejuvenate senescent T cells.

Language: Английский

Capturing Hydrophilic Chemotherapeutics Agents Into siRNA‐Encapsulated Vesicle‐Like Nanoparticles for Convenient ICB‐Chemo Combination Therapy

Small, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 5, 2024

Abstract Clinical evidence has demonstrated that combining immune checkpoint blockade (ICB) therapy with chemotherapy significantly improves response rates to ICB and therapeutic efficacy in various tumor types. However, a convenient method for achieving synergistic precise co‐delivery of both agents is still highly desirable. In this study, strategy co‐delivering small interfering RNA (siRNA) encapsulated vesicle‐like nanoparticles (VNP siRNA ) chemotherapeutic drugs aimed develop. It discovered the hydrophilic drug mitoxantrone hydrochloride (MTO·2HCl) can be captured into VNP . The resulting Cp MTO simultaneously block checkpoints via silencing induce effects on cells. mechanism MTO·2HCl elucidates, captures, demonstrates superior effect through chemo‐immunotherapy. This also extended deliver other anticancer drugs, such as doxorubicin (DOX·HCl), combination therapy. study provides facile enhancing combined offering promising approach cancer treatment.

Language: Английский

Emerging role of metabolic reprogramming in the immune microenvironment and immunotherapy of thyroid cancer

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 144, P. 113702 - 113702

Published: Nov. 26, 2024

Language: Английский